PATENT CLAIM ANALYSIS

Application Number: 16047805
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-05
Patent Classification: ["514", "365000"]

Abstract:
Provided herein are methods of cancer treatment by administering an effective amount of an endogenous ligand for the aryl hydrocarbon (Ah) receptor (AhR) named ITE or one of its structural analogs to a patient with cancer, for example, prostate, liver, lung, ovarian, breast, skin, colon (or rectum), stomach, pancreatic, kidney, bladder, soft tissue, or cervical cancer.

Claim (Index 13):
The method of  claim 10 , wherein the patient has an increased count of cells selected from the group consisting of white blood cells, neutrophils, lymphocytes, and platelets after the administering step.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 95.0
- Lexical Diversity: 1.48077
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15613808', '14961325', '13952030', '13503657', '15509722']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8251040852069995
- 35 USC 102 Novelty (BERT): 0.5894351580036103
- Combined Prediction Score: 0.8015371924866607
- Mean Citation Score: 464.73619
- Max Citation Score: 555.94995
- Similarity Product: 395.9496011024862

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test